Chonlada Laoruangroj

Chonlada Laoruangroj

Auto-generated profile, based on publicly available information

Chonlada Laoruangroj

Division of Hematology, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in JCO Oncology Practice
Verified
Journal Article
Open access
CLChonlada Laoruangroj
Chonlada Laoruangroj
THThomas M. Habermann
Thomas M. Habermann
YWYucai Wang
Yucai Wang
RKRebecca L. King
Rebecca L. King
SLScott C. Lester
Scott C. Lester
TWThomas E. Witzig
Thomas E. Witzig
PURPOSE: H. pylori eradication therapy (HPE) can lead to tumor regression in H. pylori–positive (HPP) gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, some patients do not have detectable H. pylori (HP) infection ( H. pylori–negative [HPN]) and the guidelines differ in their initial approach to HPN patients. The National Comprehensive Cancer Network (NCCN) recommends proceeding to radiation therapy, whereas European Society for Medical Oncology suggests HPE for every patient, even those who are HPN. To address this issue, we evaluated the effectiveness of HPE in limited-stage gastric MALT lymphoma. MATERIALS AND METHODS: We retrospectively reviewed patients newly diagnosed with stage IE gastric MALT lymphoma between January 2002 and December 2022. The primary outcome was the complete remission (CR) rate defined as no macroscopic findings of lymphoma and negative gastric biopsy at the follow-up gastric endoscopy. RESULTS: Fifty-two patients were reviewed, and HP infection was detected in 19 (36.5%) patients—14 by immunostaining, three by serology, and one each by stool antigen and urea breath test. All 19 HPP and eight of the 33 HPN patients received HPE treatment. The CR rate was 63% (12/19) in HPP patients and 13% (1/8) in HPN patients ( P = .033). After a median follow-up of 89.7 months, only two of the 12 HPP patients achieving CR have relapsed; the one HPN patient who received HPE remains in CR at 12+ months. CONCLUSION: For limited-stage HPP gastric MALT lymphoma, HPE is an effective and durable first-line treatment and should be used. For HPN patients, the CR rate with HPE is very low in our experience and is thus in support of the NCCN guideline.


25 November 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
KPKannadit Prayongratana
Kannadit Prayongratana
TTTanapun Thamgrang
Tanapun Thamgrang
CLChonlada Laoruangroj
Chonlada Laoruangroj
LNLalita Norasetthada
Lalita Norasetthada
TRThanawat Rattanathammethee
Thanawat Rattanathammethee
TITanin Intragumtornchai
Tanin Intragumtornchai
Objective: To describe the epidemiology, survival rate, and prognostic factors of mucosal-associated lymphoid tissue (MALT) lymphoma. Patients and Methods: This investigation utilized the Thai Lymphoma Study Group (TLSG) registry to gather data on patients diagnosed with MALT lymphoma. The analysis included demographic details, therapeutic interventions, and survival statistics. Results: The TLSG registry prospectively included 8404 patients with lymphoma. Among them, marginal-zone lymphoma (MZL) was the second most common subtype, with 670 histologically confirmed cases, accounting for 8.0% of the total cohort. An analysis of the MZL subtypes showed that MALT lymphoma was the most common, accounting for 77.8% of the diagnoses. This was followed by nodal MZL at 17.5% and splenic MZL at 7.7%. The distribution of primary disease sites indicated that the ocular adnexa (49.2%), stomach (12.9%), and sinonasal region (12.5%) were the three most common locations. Three variables were found to be statistically significant predictors of survival in the multivariate analysis: ECOG performance status > 2, age exceeding 65 years, and involvement of more than two extranodal organs. These identified prognostic factors were further assessed for their effect on overall survival (OS) and progression-free survival (PFS). A risk classification was established: the low-risk group comprised patients with zero identified risk factors, whereas the high-risk group included patients who had any of the specified risk factors. A comparison of five-year survival rates showed significantly more favorable outcomes for low-risk patients who had a PFS of 83.3% (vs. 66.1%, p = 0.028) and an OS of 97.8% (vs. 76.7%, p < 0.001) compared to the high-risk group. Conclusions: In this cohort, where MZL was the second most common lymphoma and MALT lymphoma was the predominant subtype, our analysis revealed that patients with no risk factors experienced statistically significant improvements in both PFS and OS.

6 March 2026 in Blood Research
Verified
Journal Article
Open access
PDF file
ONOytip Nathalang
Oytip Nathalang
YOYupapin Onthong
Yupapin Onthong
CLChonlada Laoruangroj
Chonlada Laoruangroj
DADollapak Apipongrat
Dollapak Apipongrat
Background: Accurate detection and monitoring of monoclonal proteins in multiple myeloma (MM) are critical for diagnosis and treatment guidance. Conventional assays such as serum protein electrophoresis (SPEP), immunofixation electrophoresis (SIFE), and serum-free light chain (SFLC) testing can yield discordant or inconclusive results, particularly in patients with low M-protein levels. Objectives: To evaluate the concordance and discordance between SIFE and SFLC assays in MM and to assess the clinical utility of the heavy/light chain (HLC) assay as a complementary quantitative tool. Methods: We retrospectively analyzed 1,310 MM patient samples. The concordance and discordance between SIFE and SFLC were assessed, and the analytical performance of HLC measurements was evaluated relative to conventional assays. Results: The overall discordance rate between SIFE and SFLC was 26.9%, with SIFE–/SFLC + most frequent in light chain MM and SIFE + /SFLC– observed in patients who achieved a very good partial response (VGPR). HLC strongly correlated with total immunoglobulins (combined immunoglobulin G [IgG]/immunoglobulin A [IgA], R 2 = 0.99) and SPEP ( R 2 = 0.94). HLC ratios demonstrated excellent concordance with SIFE ( κ = 0.83, 95% confidence interval [CI] 0.72–0.93) but poor agreement with SFLC ratios ( κ = 0.01, 95% CI − 0.18–0.20). Using the HLC response model, 15 patients classified as having VGPR by the International Myeloma Working Group (IMWG) criteria were reclassified as having a partial response due to a dHLC reduction of < 90%. Conclusions: This large retrospective study provides a comprehensive evaluation of SIFE and SFLC discordance in MM, offering real-world evidence of their complementary diagnostic and monitoring roles. These findings support the integration of HLC testing into existing response assessment strategies to enhance the accuracy of treatment evaluation and the interpretation of discordant results.

1 June 2026 in Journal of Hematology
Verified
Journal Article
Open access
PSPornpavee Siricharoenthai
Pornpavee Siricharoenthai
CTChanunya Thanoochan
Chanunya Thanoochan
PSPanachai Silpsamrit
Panachai Silpsamrit
KPKannadit Prayongratana
Kannadit Prayongratana
CLChonlada Laoruangroj
Chonlada Laoruangroj
TTTanapun Thamgrang
Tanapun Thamgrang

13 July 2026 in Blood Global Hematology
Verified
Journal Article
Open access
SSSalisa Sakulrojanawong
Salisa Sakulrojanawong
TTTanapun Thamgrang
Tanapun Thamgrang
KPKannadit Prayongratana
Kannadit Prayongratana
CLChonlada Laoruangroj
Chonlada Laoruangroj
PSPanachai Silpsamrit
Panachai Silpsamrit
RLRattapan Lamool
Rattapan Lamool